Novo issues bullish sales forecast

Share this article:
Danish diabetes giant Novo Nordisk said it expects to more than double its revenue within the decade, as the surging incidence of diabetes expands demand for its products.

As deputy chief executive Kaare Schultz told Reuters, “Today we handle more than 20 million patients. In 10 years, hopefully [we] will treat about 40 million patients,” adding, “We expect to continue to increase [revenue] by around 10% per year over the next 10 to 20 years.”

Sales could rise faster, Schultz told the news service, if Novo gets approval in the US for basal insulin Tresiba and for liraglutide for treating obesity.

The company's revenue rose 23% in the US last year to $7.9 billion, and surged 13% globally to $15.5 billion. So far, 2014 is off to a slow start, however: first-quarter sales rose only 7% after the drugmaker lost two contracts to supply a US pharmacy group.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.